Drug Patents owned by Apil

1. Drug name - ACTONEL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7192938 APIL Method of treatment using bisphosphonic acid May, 2023

(6 months from now)

US7718634 APIL Method of treatment using bisphosphonic acid May, 2023

(6 months from now)

US7718634

(Pediatric)

APIL Method of treatment using bisphosphonic acid Nov, 2023

(1 year, 1 month from now)

US7192938

(Pediatric)

APIL Method of treatment using bisphosphonic acid Nov, 2023

(1 year, 1 month from now)

Drugs and Companies using RISEDRONATE SODIUM ingredient

Treatment: Prevention and treatment of osteoporosis; Treatment of osteoporosis in postmenopausal women

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
5MG TABLET;ORAL Prescription
30MG TABLET;ORAL Prescription
35MG TABLET;ORAL Prescription
75MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** TABLET;ORAL Discontinued
150MG TABLET;ORAL Prescription

2. Drug name - ATELVIA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8246989 APIL Dosage forms of bisphosphonates Jan, 2026

(3 years from now)

US7645459 APIL Dosage forms of bisphosphonates Jan, 2028

(5 years from now)

US7645460 APIL Dosage forms of risedronate Jan, 2028

(5 years from now)

Drugs and Companies using RISEDRONATE SODIUM ingredient

Treatment: Treatment of osteoporosis in postmenopausal women

Dosage: TABLET, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
35MG TABLET, DELAYED RELEASE;ORAL Prescription

3. Drug name - FEMTRACE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7572779 APIL Oral pharmaceutical products containing 17β-estradiol-3-lower alkanoate, method of administering the same and process of preparation Oct, 2025

(2 years from now)

Drugs and Companies using ESTRADIOL ACETATE ingredient

Treatment: Treatment of moderate to severe vasomotor symptoms associated with menopause

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
0.45MG TABLET;ORAL Discontinued
0.9MG TABLET;ORAL Discontinued
1.8MG TABLET;ORAL Discontinued

4. Drug name - LO LOESTRIN FE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7704984 APIL Extended estrogen dosing contraceptive regimen Feb, 2029

(6 years from now)

Drugs and Companies using ETHINYL ESTRADIOL; NORETHINDRONE ACETATE ingredient

Treatment: Lo loestrin fe is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
0.01MG,0.01MG;1MG,N/A TABLET;ORAL Prescription

5. Drug name - LO MINASTRIN FE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7704984 APIL Extended estrogen dosing contraceptive regimen Feb, 2029

(6 years from now)

Drugs and Companies using ETHINYL ESTRADIOL; NORETHINDRONE ACETATE ingredient

Treatment: Prevention of pregnancy

Dosage: TABLET, CHEWABLE, TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
0.01MG,0.01MG,N/A;1MG,N/A,N/A TABLET, CHEWABLE, TABLET;ORAL Discontinued

availability in other generic markets.

Click on the highlighted region to filter.